Day 1 | Day 2 | Download Brochure | Short Courses
TUESDAY, AUGUST 21
1:00 pm Registration
2:15 Chairperson’s Remarks
Robin Patel, M.D., Chair, Division of Clinical Microbiology, Consultant, Divisions of Clinical Microbiology and Infectious Diseases, Professor of Microbiology and Medicine, College of Medicine, Mayo Clinic
2:20 Progress and Approaches in Developing Mass Spectrometry-Based Proteomic Assays to Distinguish Clinical Strains of Methicillin-Sensitive and Methicillin-Resistant Staphylococcus aureus
Richard R. Drake, Ph.D., Professor and Director, MUSC Proteomics Center, Medical University of South Carolina
The use of matrix-assisted laser desorption/ionization time of flight (MALDI-TOF) mass spectrometry to identify bacteria at the genus and species level is becoming standard in many clinical microbiology laboratories. Extending these methods and development of other mass spectrometry-based diagnostics for identification of strain differences within a species, particularly for clinical isolates, remains a challenge. Our group has been focusing on assay development to distinguish methicillin-sensitive (MSSA) and methicillin-resistant (MRSA) Staphylococcus aureus strains. Two primary approaches will be described. One will cover progress in implementing and further testing of a prototype MALDI-TOF three peak intensity model designed to rapidly identify USA300 family S. aureusclinical isolates. The other approach is a deeper proteomic mining comparison of different MSSA and MRSA clinical strains to identify a panel of strain-specific, differentially expressed proteins for use in further diagnostic assay development.
2:50 Rapid Detection of Beta-Lactamase Activity in Clinical Specimens by Electrospray LC/MS/MS
Michael E. Hodsdon, M.D., Ph.D., Associate Professor of Laboratory Medicine and Pharmacology, Yale University School of Medicine
Carbapenemase-expressing bacteria are associated with resistance to most modern antibiotics. Rapid diagnosis is critical to live-saving clinical care and to prevent the spread of outbreaks. We present a rapid, liquid chromatography-coupled, electrospray ionization mass spectrometric assay that detects carbapenemase activity within hours from complex biologic matrices. We are validating this method on both bacterial isolates and primary clinical specimens.
3:20 Sponsored Presentation (Opportunity Available)
3:35 Refreshment Break in the Exhibit Hall with Poster Viewing
4:10 Imaging the Effect of the Microbiome on Gut Metabolism with Mass Spectrometry with Real-Time Analysis of Bacterial Metabolic Output
Christopher Rath, Ph.D., Scientist, Dorrestein Laboratory, University of California, San Diego
Changes in gut microbiome populations have been correlated with disease status. We applied imaging mass spectrometry to localize metabolites in gnotobiotic mouse models of the human gut microbiome. Inflammation-associated molecules with altered spatial distributions include: amino-acids, bile-acids, polysaccharides, and lipids. Identifications were validated by semi-quantitative LCMS/GCMS. Findings were then correlated to human fecal samples, pure bacterial cultures, and transcriptomics analysis.
4:40 Next Generation Molecular Diagnostics: MALDI-TOF versus PCR/ESI-MS
Robert Bonomo, M.D., Associate Professor of Medicine, Division of Infectious Disease and HIV Medicine, Case Western Reserve University
The field of molecular diagnostics is rapidly changing and new platforms are introduced regularly. At present clinicians must decide the advantages and disadvantages of choosing between technologies that identify pathogens alone from technologies that reveal the resistance determinants present in bacteria. Each approach assists with decisions to initiate therapy. A comparison of technologies that use mass spectrometry (MALDI TOF and PCR/ESI-MS) will be examined.
5:10 Wine and Cheese Pairing Welcome Reception in the Exhibit Hall with Poster Viewing
6:10 Close of Day
Day 1 | Day 2 | Download Brochure | Short Courses